4,257 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Bought by 1620 Investment Advisors Inc.

1620 Investment Advisors Inc. purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 4,257 shares of the biopharmaceutical company’s stock, valued at approximately $128,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blue Trust Inc. grew its position in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 371 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of TG Therapeutics by 512.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 1,594 shares in the last quarter. Jones Financial Companies Lllp boosted its holdings in shares of TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock valued at $64,000 after acquiring an additional 1,737 shares in the last quarter. Synergy Asset Management LLC purchased a new stake in shares of TG Therapeutics in the fourth quarter valued at about $75,000. Finally, GAMMA Investing LLC boosted its holdings in shares of TG Therapeutics by 562.4% in the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 2,171 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Stock Performance

Shares of TGTX opened at $42.99 on Friday. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock has a market cap of $6.75 billion, a P/E ratio of -429.86 and a beta of 2.30. The company has a 50-day moving average of $33.17 and a two-hundred day moving average of $29.63. TG Therapeutics, Inc. has a 12-month low of $12.93 and a 12-month high of $43.15.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. The business had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. As a group, research analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Sean A. Power sold 11,337 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the completion of the transaction, the chief financial officer now owns 670,632 shares of the company’s stock, valued at approximately $20,313,443.28. This represents a 1.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TGTX. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, TG Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.